{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T03:38:58Z","timestamp":1773113938053,"version":"3.50.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2014,2,26]],"date-time":"2014-02-26T00:00:00Z","timestamp":1393372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The use of biological therapy (biologicals) is established in the treatment of Crohn's disease. This study aimed to determine whether preoperative treatment with biologicals is associated with an increased rate of complications following surgery for Crohn's disease with intestinal anastomosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>All patients receiving biologicals and undergoing abdominal surgery with anastomosis or strictureplasty were identified at six tertiary referral centres. Demographic data, and preoperative, operative and postoperative details were registered. Patients who were treated with biologicals within 2 months before surgery were compared with a control group who were not. Postoperative complications were classified according to anastomotic, infectious or other complications, and graded according to the Clavien\u2013Dindo classification.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Some 111 patients treated with biologicals within 2 months before surgery were compared with 187 patients in the control group. The groups were well matched. There were no differences between the treatment and control groups in the rate of complications of any type (34\u00b72 versus 28\u00b79 per cent respectively; P = 0\u00b7402), anastomotic complications (7\u00b72 versus 8\u00b70 per cent; P = 0\u00b7976) and non-anastomotic infectious complications (16\u00b72 versus 13\u00b79 per cent; P = 0\u00b7586). In univariable regression analysis, biologicals were not associated with an increased risk of any complication (odds ratio (OR) 1\u00b733, 95 per cent confidence interval 0\u00b781 to 2\u00b720), anastomotic complication (OR 0\u00b789, 0\u00b737 to 2\u00b717) or infectious complication (OR 1\u00b709, 0\u00b762 to 1\u00b791).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Treatment with biologicals within 2 months of surgery for Crohn's disease with intestinal anastomosis was not associated with an increased risk of complications.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/bjs.9439","type":"journal-article","created":{"date-parts":[[2014,2,26]],"date-time":"2014-02-26T11:54:42Z","timestamp":1393415682000},"page":"539-545","source":"Crossref","is-referenced-by-count":62,"title":["Complications in surgery for Crohn's disease after preoperative antitumour necrosis factor therapy"],"prefix":"10.1093","volume":"101","author":[{"given":"P","family":"Myrelid","sequence":"first","affiliation":[{"name":"Division of Surgery, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Link\u00f6ping University, and Department of Surgery, County Council of \u00d6sterg\u00f6tland, Link\u00f6ping, Sweden"},{"name":"Department of Surgery, Unit of Colorectal Surgery, Oxford University Hospitals, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Marti-Gallostra","sequence":"additional","affiliation":[{"name":"Department of Surgery, Unit of Colorectal Surgery, Oxford University Hospitals, Oxford, UK"},{"name":"Department of Surgery, University Hospital of Valle de Hebron, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Ashraf","sequence":"additional","affiliation":[{"name":"Department of Surgery, Unit of Colorectal Surgery, Oxford University Hospitals, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M L","family":"Sunde","sequence":"additional","affiliation":[{"name":"Clinic for Surgical Sciences, Faculty of Medicine, University of Oslo, Oslo, and Department of Gastrointestinal Surgery, Akershus University Hospital, Lorenskog, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Tholin","sequence":"additional","affiliation":[{"name":"Division of Surgery, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Link\u00f6ping University, and Department of Surgery, County Council of \u00d6sterg\u00f6tland, Link\u00f6ping, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"\u00d8resland","sequence":"additional","affiliation":[{"name":"Clinic for Surgical Sciences, Faculty of Medicine, University of Oslo, Oslo, and Department of Gastrointestinal Surgery, Akershus University Hospital, Lorenskog, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R E","family":"Lovegrove","sequence":"additional","affiliation":[{"name":"Department of Surgery, Unit of Colorectal Surgery, Oxford University Hospitals, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"T\u00f8ttrup","sequence":"additional","affiliation":[{"name":"Surgical Gastroenterological Department P, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D W","family":"Kj\u00e6r","sequence":"additional","affiliation":[{"name":"Surgical Gastroenterological Department P, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B D","family":"George","sequence":"additional","affiliation":[{"name":"Department of Surgery, Unit of Colorectal Surgery, Oxford University Hospitals, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,2,26]]},"reference":[{"key":"2021031210205484900_bjs9439-bib-0001","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/BF02236563","article-title":"Risk factors for intra-abdominal sepsis after surgery in Crohn's disease","volume":"43","author":"Yamamoto","year":"2000","journal-title":"Dis Colon Rectum"},{"key":"2021031210205484900_bjs9439-bib-0002","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/j.1365-2036.2011.04598.x","article-title":"Review article: infliximab for Crohn's disease treatment \u2013 shifting therapeutic strategies after 10 years of clinical experience","volume":"33","author":"Danese","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"2021031210205484900_bjs9439-bib-0003","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"et al.; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"2021031210205484900_bjs9439-bib-0004","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/SLA.0b013e3181e61df5","article-title":"Trends in surgery for Crohn's disease in the era of infliximab","volume":"252","author":"Jones","year":"2010","journal-title":"Ann Surg"},{"key":"2021031210205484900_bjs9439-bib-0005","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cgh.2007.02.016","article-title":"Serious adverse events with infliximab: analysis of spontaneously reported adverse events","volume":"5","author":"Hansen","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021031210205484900_bjs9439-bib-0006","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrgastro.2009.221","article-title":"Optimizing the safety of biologic therapy for IBD","volume":"7","author":"de Silva","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2021031210205484900_bjs9439-bib-0007","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/j.1572-0241.2004.04148.x","article-title":"Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy","volume":"99","author":"Colombel","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"2021031210205484900_bjs9439-bib-0008","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0039-6060(03)00298-8","article-title":"Multivariate analysis suggests improved perioperative outcome in Crohn's disease patients receiving immunomodulator therapy after segmental resection and\/or strictureplasty","volume":"134","author":"Tay","year":"2003","journal-title":"Surgery"},{"key":"2021031210205484900_bjs9439-bib-0009","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1365-2036.2004.01904.x","article-title":"The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study","volume":"19","author":"Marchal","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"2021031210205484900_bjs9439-bib-0010","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1007\/s11605-008-0646-0","article-title":"Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients","volume":"12","author":"Appau","year":"2008","journal-title":"J Gastrointest Surg"},{"key":"2021031210205484900_bjs9439-bib-0011","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1007\/s11605-008-0630-8","article-title":"Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications","volume":"12","author":"Kunitake","year":"2008","journal-title":"J Gastrointest Surg"},{"key":"2021031210205484900_bjs9439-bib-0012","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/j.1463-1318.2010.02469.x","article-title":"Surgical resection in Crohn's disease: is immunosuppressive medication associated with higher postoperative infection rates?","volume":"13","author":"Canedo","year":"2011","journal-title":"Colorectal Dis"},{"key":"2021031210205484900_bjs9439-bib-0013","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/ibd.21860","article-title":"Infliximab does not affect postoperative complication rates in Crohn's patients undergoing abdominal surgery","volume":"18","author":"Kasparek","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2021031210205484900_bjs9439-bib-0014","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00384-011-1236-2","article-title":"Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience","volume":"26","author":"Rizzo","year":"2011","journal-title":"Int J Colorectal Dis"},{"key":"2021031210205484900_bjs9439-bib-0015","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00268-009-9957-x","article-title":"Effect of perioperative immunosuppressive medication on early outcome in Crohn's disease patients","volume":"33","author":"Indar","year":"2009","journal-title":"World J Surg"},{"key":"2021031210205484900_bjs9439-bib-0016","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1463-1318.2010.02186.x","article-title":"Short-term outcome of infliximab and other medications on patients with inflammatory bowel disease undergoing ileostomy reversal","volume":"13","author":"Regadas","year":"2011","journal-title":"Colorectal Dis"},{"key":"2021031210205484900_bjs9439-bib-0017","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/gutjnl-2011-301495","article-title":"Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease","volume":"62","author":"Waterman","year":"2013","journal-title":"Gut"},{"key":"2021031210205484900_bjs9439-bib-0018","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Ther"},{"key":"2021031210205484900_bjs9439-bib-0019","doi-asserted-by":"crossref","first-page":"5A","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology","volume":"19","author":"Silverberg","year":"2005","journal-title":"Can J Gastroenterol"},{"key":"2021031210205484900_bjs9439-bib-0020","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/DCR.0b013e3181a7ba96","article-title":"Thiopurine therapy is associated with postoperative intra-abdominal septic complications in abdominal surgery for Crohn's disease","volume":"52","author":"Myrelid","year":"2009","journal-title":"Dis Colon Rectum"},{"key":"2021031210205484900_bjs9439-bib-0021","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"2021031210205484900_bjs9439-bib-0022","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/bjs.5179","article-title":"Long-term follow-up of strictureplasty for Crohn's disease","volume":"93","author":"Fearnhead","year":"2006","journal-title":"Br J Surg"},{"key":"2021031210205484900_bjs9439-bib-0023","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00000658-199101000-00007","article-title":"Risks of intestinal anastomoses in Crohn's disease","volume":"213","author":"Post","year":"1991","journal-title":"Ann Surg"},{"key":"2021031210205484900_bjs9439-bib-0024","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1002\/ibd.22954","article-title":"Anti-tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta-analysis","volume":"18","author":"Kopylov","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2021031210205484900_bjs9439-bib-0025","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.crohns.2013.01.019","article-title":"The risks of post-operative complications following pre-operative infliximab therapy for Crohn's disease in patients undergoing abdominal surgery: a systematic review and meta-analysis","volume":"7","author":"Rosenfeld","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2021031210205484900_bjs9439-bib-0026","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2036.2009.04204.x","article-title":"Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis","volume":"31","author":"Yang","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"2021031210205484900_bjs9439-bib-0027","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jamcollsurg.2006.12.044","article-title":"Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis","volume":"204","author":"Selvasekar","year":"2007","journal-title":"J Am Coll Surg"},{"key":"2021031210205484900_bjs9439-bib-0028","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/ibd.20863","article-title":"Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis","volume":"15","author":"Ferrante","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"2021031210205484900_bjs9439-bib-0029","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/rheumatology\/keq249a","article-title":"Standards, Audit and Guidelines Working Group of BSR Clinical Affairs Committee; BHPR. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies","volume":"49","author":"Ding","year":"2010","journal-title":"Rheumatology (Oxford)"}],"container-title":["British Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbjs.9439","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/bjs\/article-pdf\/101\/5\/539\/36581506\/bjs9439.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/bjs\/article-pdf\/101\/5\/539\/36581506\/bjs9439.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T14:10:56Z","timestamp":1621519856000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjs\/article\/101\/5\/539-545\/6138072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,26]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,2,26]]},"published-print":{"date-parts":[[2014,3,13]]}},"URL":"https:\/\/doi.org\/10.1002\/bjs.9439","relation":{},"ISSN":["0007-1323","1365-2168"],"issn-type":[{"value":"0007-1323","type":"print"},{"value":"1365-2168","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,4]]},"published":{"date-parts":[[2014,2,26]]}}}